<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370641</url>
  </required_header>
  <id_info>
    <org_study_id>12-000874</org_study_id>
    <nct_id>NCT02370641</nct_id>
  </id_info>
  <brief_title>Effects of Pomegranate Extract on Intestinal Flora</brief_title>
  <acronym>PomX</acronym>
  <official_title>Variations in Urolithin Production by the Microbiome After Pomegranate Extract Administration: Understanding Metabolism and Responsiveness to Pomegranate Ellagitannins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 20 individuals, 10 urolithin excretors and 10 nonexcretors will be enrolled. The
      excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine
      after one dose of POMx. A blood sample and stool sample will be obtained before administering
      the extract. Subjects will be asked to consume one capsule of 1000 mg POMx daily for 4 weeks.
      At day 28, a blood sample, 24 hour urine sample will be obtained, and the stool collected by
      the participant in the prior 24 hours will be returned to the Center. Blood and urine
      urolithin, ellagic acid levels and stool bacteria enumeration and identification (including
      pyrosequencing) will be measured with the samples collected. A stool DNA sample will be
      preserved and frozen for potential future measurement of gene-nutrient interaction in
      pomegranate metabolism.

      Throughout the study participants will be instructed not to consume pomegranate products,
      walnuts, or polyphenol-rich fruits ((strawberry, raspberry etc) or juices drawn from a list
      used in prior studies. The study will be carried out in accordance with the guidelines of the
      Human Subjects Protection Committee of the University of California, Los Angeles. All
      subjects will give written informed consent before the study begins. Participants will be
      recruited by advertisement in the local newspaper in the Los Angeles Area close to UCLA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At screening, informed consent and health insurance portability and assurance (HIPAA)
      authorization will be reviewed and signed. A medical history will be obtained. If criteria
      for enrollment are satisfied, a fasting blood sample will be collected for a comprehensive
      metabolic panel, and blood count. Results will be reviewed by the study physician for
      compliance to inclusion and exclusion criteria. The screening visit will also include a
      review of foods to avoid during run-in and study participation. Once lab results from the
      screening visit come back and are determined to be satisfactory for inclusion, the subject
      will be called and instructed to start dietary restrictions. The first stool collection (Day
      -1) will occur after two weeks of dietary compliance.

      Day -1: Subjects will be asked to collect an entire stool and store it in a cooler filled
      with ice packs, along with a collection container until delivery to the lab within 24 hours.

      Day 1: Subjects will take the 1st dose of POMx and be given a container for collecting their
      urine for 24 hours and asked to refrigerate this as the urine is collected. This urine will
      be used to determine the presence of urolithin A and whether they are &quot;responder or non
      responder&quot;. Participants will be asked to consume 1 POMx capsule daily and to abstain from
      consuming pomegranates, walnuts, or polyphenol-rich foods or juices drawn from a list.

      Day 27: Subjects will collect one entire stool and place in the provided cooler filled with
      ice packs for storage of the stool sample until delivery to the lab within 24 h. Urine
      collection will start at 8am after the morning dose of POMx and last until 8 am the day of
      clinic visit.

      Day 28: Stool and urine sample will be collected. The stool sample collected at home (within
      the prior 24 hours) will be returned on this day. Blood sample will be collected. Compliance
      will be assessed by pill count. Safety and tolerance data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors</measure>
    <time_frame>4 weeks</time_frame>
    <description>Difference of percentage of total microflora between urolithin excretors and non-excretors after consumption of pomegranate extract for 4 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Urolith</condition>
  <arm_group>
    <arm_group_label>urolithin excretors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non excretors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PomX</intervention_name>
    <description>1000 mg POMx daily for 4 weeks</description>
    <arm_group_label>non excretors</arm_group_label>
    <arm_group_label>urolithin excretors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20-50 years of age at screen.

          2. In good health

          3. Subjects must read and sign the Institutional Review Board-approved written informed
             consent prior to the initiation of any study specific procedures or enrollment. A
             subject will be excluded for any condition that might compromise the ability to give
             truly informed consent.

        Exclusion Criteria:

          1. Any history of gastrointestinal disease except for appendectomy

          2. Any use of antibiotics or laxatives during the 2 months prior to study enrollment.

          3. Any subject with a history of diabetes mellitus, or other serious medical condition,
             such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease,
             chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft,
             angioplasty within 6 months prior to screening, current diagnosis of uncontrolled
             hypertension (defined as systolic BP&gt;160mmHg, diastolic BP&gt;95mmHg), active or chronic
             gastrointestinal disorders, bulimia, anorexia, or endocrine diseases (except thyroid
             disease requiring medication) as indicated by medical history or routine physical
             examination.

          4. Any subject consuming pre- or probiotics

          5. Any subject with a screening laboratory value outside of the laboratory normal range
             that is considered clinically significant for study participation by the investigator.

          6. Any subject who currently uses tobacco products or has used tobacco products within
             the last year.

          7. Any subject who is unable or unwilling to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoping Li, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Department of Medicine, Division of Clinical Nutrition</affiliation>
  </overall_official>
  <results_reference>
    <citation>Li Z, Henning SM, Lee RP, Lu QY, Summanen PH, Thames G, Corbett K, Downes J, Tseng CH, Finegold SM, Heber D. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015 Aug;6(8):2487-95. doi: 10.1039/c5fo00669d. Epub 2015 Jul 20.</citation>
    <PMID>26189645</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>October 4, 2018</results_first_submitted>
  <results_first_submitted_qc>August 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2019</results_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Zhaoping Li</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>urolithin A</keyword>
  <keyword>microflora</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD with other researchers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment period was 10/31/2012 - 7/2/2013. Enrollment took place in a private setting in the clinic located at the site.</recruitment_details>
      <pre_assignment_details>Twenty-six healthy participants were enrolled in the study. There were two study phases including a 2-week run-in period and a 4-week intervention period. Six subjects who did not complete the study were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Urolithin Excretors</title>
          <description>The excretor status was determined by analysis of urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample were obtained before administering the extract.
PomX: 1000 mg POMx daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Non Excretors</title>
          <description>The excretor status was determined by the analysis of urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample were obtained before administering the extract.
PomX: 1000 mg POMx daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>dropped study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Urolithin Excretors</title>
          <description>The excretor status was determined by analysis of urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample were obtained before administering the extract.
PomX: 1000 mg POMx daily for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Non Excretors</title>
          <description>The excretor status was determined by the analysis of urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample were obtained before administering the extract.
PomX: 1000 mg POMx daily for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="3"/>
                    <measurement group_id="B2" value="23" spread="3"/>
                    <measurement group_id="B3" value="23" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors</title>
        <description>Difference of percentage of total microflora between urolithin excretors and non-excretors after consumption of pomegranate extract for 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microbial Phylum Abundance in Urolithin Excretors</title>
            <description>Microbial phylum abundance (% of total) in urolithin excretors after consumption of 1000 mg pomegranate extract daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Microbial Phylum Abundance in Non Excretors</title>
            <description>Microbial phylum abundance (% of total) in urolithin excretors after consumption of 1000 mg pomegranate extract daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors</title>
          <description>Difference of percentage of total microflora between urolithin excretors and non-excretors after consumption of pomegranate extract for 4 weeks</description>
          <units>percentage of total microflora</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of phylum Firmecutes at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="10.1"/>
                    <measurement group_id="O2" value="68" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of phylum Firmecutes at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="10.5"/>
                    <measurement group_id="O2" value="70" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of phylum Proteobacteria at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.5"/>
                    <measurement group_id="O2" value="2.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of phylum Proteobacteria at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="5.4"/>
                    <measurement group_id="O2" value="1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to week 4 minus baseline change of phylum Firmicutes abundance between urolithin excretors and non excretors</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>p&lt;0.05 is defined as significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to week 4 minus baseline change of phylum Proteobacteria abundance between urolithin excretors and non excretors</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>p&lt;0.05 was defined as significant</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over a 4 week period</time_frame>
      <desc>Participants were monitored and questioned regarding the occurrence and nature of any adverse experiences.</desc>
      <group_list>
        <group group_id="E1">
          <title>Microbial Phylum Abundance in Urolithin Excretors</title>
          <description>microbial phylum abundance in urolithin excretors after consumption of 1000 mg pomegranate extract daily for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Microbial Phylum Abundance in Urolithin Non Excretors</title>
          <description>The excretor status was determined by the analysis of urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample were obtained before administering the extract.
PomX: 1000 mg POMx daily for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea after taking supplement on empty stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>mild gastrointestinal discomfort after taking supplement on empty stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zhaoping Li, Professor</name_or_title>
      <organization>UCLA Department of Medicine/Center for Human Nutrition</organization>
      <phone>310-206-1987</phone>
      <email>zli@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

